131 related articles for article (PubMed ID: 27389174)
1. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.
Jewell RC; Kipps TJ; Dürig J; Griskevicius L; Stilgenbauer S; Smolej L; Mayer J; Hess G; Hernandez-Ilizaliturri FJ; Padmanabhan-Iyer S; Fang L; Goldstein N; Gorczyca M; Gupta I; Lisby S; Wierda WG;
Leuk Lymphoma; 2017 Feb; 58(2):348-356. PubMed ID: 27389174
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
[TBL] [Abstract][Full Text] [Related]
3. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab in the treatment of chronic lymphocytic leukemia.
Tsimberidou AM
Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
[TBL] [Abstract][Full Text] [Related]
5. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Robak T; Warzocha K; Govind Babu K; Kulyaba Y; Kuliczkowski K; Abdulkadyrov K; Loscertales J; Kryachok I; Kłoczko J; Rekhtman G; Homenda W; Błoński JZ; McKeown A; Gorczyca MM; Carey JL; Chang CN; Lisby S; Gupta IV; Grosicki S
Leuk Lymphoma; 2017 May; 58(5):1084-1093. PubMed ID: 27731748
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Dürig J; Griskevicius L; Stilgenbauer S; Mayer J; Smolej L; Hess G; Griniute R; Hernandez-Ilizaliturri FJ; Padmanabhan S; Gorczyca M; Chang CN; Chan G; Gupta I; Nielsen TG; Russell CA;
Blood; 2011 Jun; 117(24):6450-8. PubMed ID: 21498674
[TBL] [Abstract][Full Text] [Related]
7. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
[TBL] [Abstract][Full Text] [Related]
8. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Österborg A; Udvardy M; Zaritskey A; Andersson PO; Grosicki S; Mazur G; Kaplan P; Steurer M; Schuh A; Montillo M; Kryachok I; Middeke JM; Kulyaba Y; Rekhtman G; Gorczyca M; Daly S; Chang CN; Lisby S; Gupta I
Leuk Lymphoma; 2016 Sep; 57(9):2037-46. PubMed ID: 26784000
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
10. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.
van Oers M; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Davis J; Banerjee H; Stefanelli T; Hoever P; Geisler C
Blood Cancer J; 2019 Dec; 9(12):98. PubMed ID: 31801940
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.
Moreno C; Montillo M; Panayiotidis P; Dimou M; Bloor A; Dupuis J; Schuh A; Norin S; Geisler C; Hillmen P; Doubek M; Trněný M; Obrtlikova P; Laurenti L; Stilgenbauer S; Smolej L; Ghia P; Cymbalista F; Jaeger U; Stamatopoulos K; Stavroyianni N; Carrington P; Zouabi H; Leblond V; Gomez-Garcia JC; Rubio M; Marasca R; Musuraca G; Rigacci L; Farina L; Paolini R; Pospisilova S; Kimby E; Bradley C; Montserrat E
Haematologica; 2015 Apr; 100(4):511-6. PubMed ID: 25596264
[TBL] [Abstract][Full Text] [Related]
12. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
13. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.
Flinn IW; Panayiotidis P; Afanasyev B; Janssens A; Grosicki S; Homenda W; Smolej L; Kuliczkowski K; Doubek M; Domnikova N; West SL; Chang CN; Barker AM; Gupta IV; Wright OJ; Offner F
Am J Hematol; 2016 Sep; 91(9):900-6. PubMed ID: 27222473
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.
Hillmen P; Janssens A; Babu KG; Kloczko J; Grosicki S; Manson S; McKeown A; Gupta I; Chang CN; Offner F
Acta Oncol; 2016; 55(9-10):1115-1120. PubMed ID: 27494089
[TBL] [Abstract][Full Text] [Related]
17. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
19. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
Strati P; Lanasa M; Call TG; Leis JF; Brander DM; LaPlant BR; Pettinger AM; Ding W; Parikh SA; Hanson CA; Chanan-Khan AA; Bowen DA; Conte M; Kay NE; Shanafelt TD
Lancet Haematol; 2016 Sep; 3(9):e407-14. PubMed ID: 27570087
[TBL] [Abstract][Full Text] [Related]
20. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
